Mark G. Kris focuses on Lung cancer, Internal medicine, Oncology, Cancer and Adenocarcinoma. His Lung cancer study combines topics from a wide range of disciplines, such as Surgery, Radiation therapy, Cancer research and Performance status. In Internal medicine, Mark G. Kris works on issues like Gastroenterology, which are connected to Docetaxel.
His Oncology research integrates issues from Targeted therapy, Carcinoma, Disease and Clinical trial. As part of one scientific family, Mark G. Kris deals mainly with the area of Cancer, narrowing it down to issues related to the MEDLINE, and often Emergency medicine, Intensive care medicine and Common Terminology Criteria for Adverse Events. His research integrates issues of Mutation, KRAS, Lung, Exon and Stage in his study of Adenocarcinoma.
Mark G. Kris mostly deals with Internal medicine, Oncology, Lung cancer, Chemotherapy and Cancer research. His studies link Gastroenterology with Internal medicine. His studies examine the connections between Oncology and genetics, as well as such issues in Docetaxel, with regards to Vinorelbine.
His Lung cancer research incorporates elements of Cancer, Carcinoma and Clinical trial. His Chemotherapy research incorporates themes from Anesthesia, Vomiting and Toxicity. His Cancer research research incorporates themes from Mutation, Tyrosine kinase, Drug resistance and Exon.
His primary scientific interests are in Internal medicine, Oncology, Lung cancer, Lung and Cancer research. His biological study spans a wide range of topics, including Immunohistochemistry, Phases of clinical research, Atezolizumab, Hazard ratio and Stage. His Lung cancer research is multidisciplinary, relying on both Cancer, Targeted therapy, Adenocarcinoma and Mutation, KRAS.
In his research on the topic of Cancer, Cohort is strongly related with Carcinoma. His studies in Cancer research integrate themes in fields like Tyrosine kinase, Mutant, Exon, Drug resistance and Osimertinib. He interconnects Erlotinib and Epidermal growth factor receptor in the investigation of issues within Mutant.
His primary areas of investigation include Lung cancer, Internal medicine, Oncology, Cancer and Cancer research. His Lung cancer research integrates issues from Mutation, KRAS, Targeted therapy, Exon and Adenocarcinoma. His research in Oncology intersects with topics in Etoposide, Prospective cohort study, Surgery and Toxicity.
His Cancer research incorporates elements of Genotyping, Adverse effect, Immunology and Retrospective cohort study. His Cancer research study integrates concerns from other disciplines, such as Clinical trial, Navitoclax, Kinase, Drug resistance and Osimertinib. His research investigates the connection with Erlotinib and areas like Adjuvant which intersect with concerns in Epidermal growth factor receptor and Gastroenterology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
William Pao;Vincent Miller;Maureen Zakowski;Jennifer Doherty.
Proceedings of the National Academy of Sciences of the United States of America (2004)
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
William Pao;Vincent A. Miller;Katerina A Politi;Gregory J. Riely.
PLOS Medicine (2005)
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients with Non-Small Cell Lung Cancer: A Randomized Trial
Mark G. Kris;Mark G. Kris;Ronald B. Natale;Roy S. Herbst;Thomas J. Lynch.
Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens
Frank V. Fossella;Russell DeVore;Ronald N. Kerr;Jeffrey Crawford.
Journal of Clinical Oncology (2000)
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Helena A. Yu;Maria E. Arcila;Natasha Rekhtman;Camelia S. Sima.
Clinical Cancer Research (2013)
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
William Pao;Theresa Y Wang;Gregory J Riely;Vincent A Miller.
PLOS Medicine (2005)
TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer
Roy S. Herbst;Diane Prager;Robert Hermann;Lou Fehrenbacher.
Journal of Clinical Oncology (2005)
Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer
Jeffrey Crawford;Howard Ozer;Ronald Stoller;David H Johnson.
The New England Journal of Medicine (1991)
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Mark G. Kris;Bruce E. Johnson;Lynne D. Berry;David J. Kwiatkowski.
Non–Small Cell Lung Cancer
David S. Ettinger;Wallace Akerley;Gerold Bepler;Andrew Chang.
Journal of The National Comprehensive Cancer Network (2010)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: